Security key
59564R807
Biodexa Pharmaceuticals Plc - Ordinary Shares, nominal value 0.00005 GBP per share (BDRX)
CUSIP: 59564R807
Q4 2024 13F Holders as of 31 Dec 2024
- Security type / class
- Equity / Ordinary Shares, nominal value 0.00005 GBP per share
- Total 13F shares
- 7,242
- Total 13F value
- $29,334
- Share change
- +7,241
- SEC-reported price per share
- $4.05
- Number of holders
- 4
- Value change
- +$29,330
- Number of buys
- 3
- Shares outstanding
- 25,770,441,176
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
4
Top holders
4
BDRX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Biodexa Pharmaceuticals Plc SEC filings
Biodexa Pharmaceuticals Plc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 59564R807
Recent filing periods:
Ownership snapshot
Top reported holders of BDRX - Biodexa Pharmaceuticals Plc - Ordinary Shares, nominal value 0.00005 GBP per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
UBS Group AG
Disclosed value leader
UBS Group AG
Comparable rows
0/6
Latest evidence
30 Sep 2024
13F
Highest disclosed value: $72,036
6 rows are not safely comparable across share classes.
Quick read
UBS Group AG has the largest disclosed position value at $72K.
0 of 6 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens UBS Group AG's linked filing trail.
Disclosed position value
Top 5
UBS Group AG
$72K
TWO SIGMA SECURITIES, LLC
$9.2K
MORGAN STANLEY
$4K
RHUMBLINE ADVISERS
$1.7K
CONTRAVISORY INVESTMENT MANAGEMEN...
$282
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 6 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| UBS Group AG |
13F
Company
|
—
class O/S missing
|
$72,036
255,446 shares
|
— | 30 Sep 2024 |
| TWO SIGMA SECURITIES, LLC |
13F
Company
|
—
class O/S missing
|
$9,193
32,577 shares
|
— | 30 Sep 2024 |
| MORGAN STANLEY |
13F
Company
|
—
class O/S missing
|
$4,041
14,320 shares
|
— | 30 Sep 2024 |
| RHUMBLINE ADVISERS |
13F
Company
|
—
class O/S missing
|
$1,701
6,038 shares
|
— | 30 Sep 2024 |
| CONTRAVISORY INVESTMENT MANAGEMENT, INC. |
13F
Company
|
—
class O/S missing
|
$282
1,000 shares
|
— | 30 Sep 2024 |
| GAMMA Investing LLC |
13F
Company
|
—
class O/S missing
|
$81
287 shares
|
— | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
4
Shares
7,242
Rows available
4
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
0
Q4 2024 holders
4
Holder diff
4
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend